PD-L1-IN-11

PD-L1-IN-11 (APBC) (3.125-100 μM) binds directly to recombinant human PD-L1 protein with a K_D of 49.50 μM^[2].
PD-L1-IN-11 (50-100 μM) inhibits the PD-1/PD-L1 protein-protein interaction with an IC₅₀ of 27.82 μM, reaching 65.1% blocking efficiency at 100 μM^[2].
PD-L1-IN-11 (25-50 μM; 30 min) blocks the interaction between hPD-L1 protein and hPD-1-expressing Jurkat cells, with 10.2% efficiency at 25 μM and 37.3% efficiency at 50 μM, without inducing cell toxicity^[2].
PD-L1-IN-11 (5-25 μM; 48 h coculture) dose-dependently enhances IFN-γ and TNF-α secretion from preactivated human CD4⁺ T cells cocultured with hPD-L1-expressing NCI-H1975 cells, restoring PD-L1-mediated T cell suppression^[2].
PD-L1-IN-11 (10-50 μM; 48 h coculture) dose-dependently enhances TNF-α secretion from preactivated human CD4⁺ T cells cocultured with hPD-L1-overexpressing HEK293T cells, with effects dependent on PD-1/PD-L1 blockade^[2].
PD-L1-IN-11 (200 μM; 24-48 h) has minimal cytotoxicity, with inhibition ratios below 25.6% at 200 μM after 24 or 48 h incubation with B16F10-hPD-L1, HeLa, BIC-1, and primary human CD4⁺ T cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.